carbamates has been researched along with carbazeran in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (53.85) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (23.08) | 24.3611 |
| 2020's | 2 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Rodger, IW; Shahid, M | 1 |
| Houslay, MD; Price, B; Pyne, NJ | 1 |
| Kaye, B; Rance, DJ; Waring, L | 1 |
| Carlier, J; D'Orio, V; el Allaf, D | 1 |
| Elliott, HL; Hillis, WS; Kaye, B; Offerman, JL; Reid, JL | 1 |
| Been, M; Hillis, WS | 1 |
| Baird, JR; Blackburn, KJ; Cambridge, D; Constantine, JW; Ghaly, MS; Hayden, ML; McIlhenny, HM; Moore, PF; Olukotun, AY; Pullman, LG; Salsburg, DS; Saxton, CA; Shevde, S; Taylor, CR | 1 |
| Beedham, C; Critchley, DJ; Rance, DJ | 1 |
| Clark, AJ; Gao, H; Obach, RS; Ripp, SL; Schildknegt, K; Sharma, R; Spracklin, DK; Strelevitz, TJ; Tremaine, LM; Vaz, AD | 1 |
| Balavenkatraman, KK; Bertschi, B; Camenisch, G; Kretz, O; Ling, B; Litherland, K; Manevski, N; Pognan, F; Schaefer, DJ; Schiller, H; Swart, P; Walles, M; Wettstein, R; Wolf, A | 1 |
| Chen, S; Lau, AJ; Saburulla, NF; Wong, SY; Xie, J; Yap, ZP; Zhang, LH | 1 |
| Bolleddula, J; Chowdhury, S; Kato, S; Miyata, Y; Plesescu, M; Shah, A; Zhu, X | 1 |
| Ahire, DS; Cronin, CN; Heyward, S; Jones, RS; Khojasteh, SC; Kulkarni, P; Murray, BP; Prasad, B; Singh, DK; Smith, BJ; Subash, S; Zientek, MA | 1 |
3 review(s) available for carbamates and carbazeran
| Article | Year |
|---|---|
The new inotropic phosphodiesterase inhibitors.
Topics: Aminopyridines; Amrinone; Calcium; Carbamates; Cardiotonic Agents; Cardiovascular Agents; Enoximone; Heart Failure; Hemodynamics; Humans; Imidazoles; Milrinone; Myocardial Contraction; Phosphodiesterase Inhibitors; Pyridones; Quinazolines; Stimulation, Chemical; Time Factors; Xanthines | 1984 |
Phosphodiesterase inhibitors: haemodynamic effects related to the treatment of cardiac failure.
Topics: Aminophylline; Animals; Carbamates; Heart Failure; Heart Rate; Hemodynamics; Humans; Myocardial Contraction; Phosphodiesterase Inhibitors; Quinazolines; Stimulation, Chemical | 1982 |
Comparative pharmacology and clinical efficacy of newer agents in treatment of heart failure.
Topics: Animals; Asthma; Carbamates; Cardiotonic Agents; Cardiovascular Agents; Clinical Trials as Topic; Drug Evaluation; Drug Evaluation, Preclinical; Ethanolamines; Heart Failure; Hemodynamics; Humans; Hypertension; Piperazines; Prazosin; Quinazolines; Vasodilator Agents | 1981 |
1 trial(s) available for carbamates and carbazeran
| Article | Year |
|---|---|
Comparative pharmacology and clinical efficacy of newer agents in treatment of heart failure.
Topics: Animals; Asthma; Carbamates; Cardiotonic Agents; Cardiovascular Agents; Clinical Trials as Topic; Drug Evaluation; Drug Evaluation, Preclinical; Ethanolamines; Heart Failure; Hemodynamics; Humans; Hypertension; Piperazines; Prazosin; Quinazolines; Vasodilator Agents | 1981 |
10 other study(ies) available for carbamates and carbazeran
| Article | Year |
|---|---|
Chronotropic and inotropic actions of amrinone, carbazeran and isobutylmethyl xanthine: role of phosphodiesterase inhibition.
Topics: 1-Methyl-3-isobutylxanthine; Amrinone; Animals; Carbamates; Cardiovascular Agents; Cyclic AMP; Cyclic GMP; Electric Stimulation; Heart; Heart Rate; In Vitro Techniques; Isoproterenol; Male; Myocardial Contraction; Papillary Muscles; Phosphodiesterase Inhibitors; Rabbits; Theophylline | 1989 |
Proteolysis of cyclic AMP phosphodiesterase-II attenuates its ability to be inhibited by compounds which exert positive inotropic actions in cardiac tissue.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; 3',5'-Cyclic-GMP Phosphodiesterases; Amrinone; Animals; Carbamates; Cardiotonic Agents; Cyclic AMP; Cyclic GMP; Dogs; Kinetics; Milrinone; Myocardium; Peptide Hydrolases; Pyridazines; Pyridones; Quinazolines; Trypsin | 1987 |
Oxidative metabolism of carbazeran in vitro by liver cytosol of baboon and man.
Topics: Aldehyde Oxidase; Aldehyde Oxidoreductases; Animals; Carbamates; Cytosol; Dogs; Humans; Hydroxylation; In Vitro Techniques; Liver; Papio; Species Specificity | 1985 |
A species difference in the presystemic metabolism of carbazeran in dog and man.
Topics: Adult; Animals; Biological Availability; Biotransformation; Carbamates; Chemical Phenomena; Chemistry; Dogs; Humans; Male; Species Specificity | 1984 |
Biotransformation of carbazeran in guinea pig: effect of hydralazine pretreatment.
Topics: Aldehyde Oxidase; Aldehyde Oxidoreductases; Animals; Biotransformation; Carbamates; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Feces; Guinea Pigs; Hydralazine; Hydrolysis; Liver; Male | 1994 |
Deuterium isotope effects on drug pharmacokinetics. I. System-dependent effects of specific deuteration with aldehyde oxidase cleared drugs.
Topics: Aldehyde Oxidase; Animals; Carbamates; Cytosol; Deuterium; Guanidines; Guinea Pigs; Hepatocytes; Humans; Kinetics; Liver; Male; Pyrazoles; Rats; Rats, Sprague-Dawley | 2012 |
Aldehyde oxidase activity in fresh human skin.
Topics: Adult; Aged; Aldehyde Oxidase; Carbamates; Female; Guanidines; Humans; Hydralazine; Hydroxylation; Kinetics; Male; Metabolic Detoxication, Phase II; Middle Aged; Pyrazoles; Skin; Toluidines | 2014 |
Evaluation of Carbazeran 4-Oxidation and
Topics: Aldehyde Oxidase; Biocatalysis; Biomarkers; Calibration; Carbamates; Cytochrome P-450 Enzyme System; Cytosol; Drug Development; Guanine; Humans; Microsomes, Liver; Oxidation-Reduction; Reference Standards | 2019 |
Prediction of Human Disproportionate and Biliary Excreted Metabolites Using Chimeric Mice with Humanized Liver.
Topics: Animals; Bile; Biotransformation; Carbamates; Cyproheptadine; Drug Evaluation, Preclinical; Hepatobiliary Elimination; Hepatocytes; Humans; Liver; Loratadine; Male; Mianserin; Mice; Transplantation Chimera | 2020 |
Dissecting Parameters Contributing to the Underprediction of Aldehyde Oxidase-Mediated Metabolic Clearance of Drugs.
Topics: Aldehyde Oxidase; Carbamates; Humans; Kinetics; Liver; Metabolic Clearance Rate | 2023 |